Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Number of holders
-
24
-
Total principal
-
279M
-
Principal change
-
+9.68M
-
Total reported value, excl. options
-
$202M
-
Value change
-
+$5.83M
-
Number of buys
-
5
-
Number of sells
-
-11
-
Price
-
$0.76
Significant Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q4 2023
22 filings reported holding 761330AB5 - REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q4 2023.
REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 has 24 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $279M of principal
.
Largest 10 bondholders include FRANKLIN RESOURCES INC ($44M of principal), D. E. Shaw & Co., Inc. ($38.1M of principal), Graham Capital Management, L.P. ($31.9M of principal), UBS OCONNOR LLC ($31.5M of principal), Context Capital Management, LLC ($31.2M of principal), AVIVA PLC ($22.3M of principal), HIGHBRIDGE CAPITAL MANAGEMENT LLC ($20M of principal), SILVERBACK ASSET MANAGEMENT LLC ($14M of principal), Nuveen Asset Management, LLC ($14M of principal), and SSI INVESTMENT MANAGEMENT LLC ($7.84M of principal).
This table shows the top 24 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.